We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Array Technologies Inc | NASDAQ:ARRY | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.40 | 3.06% | 13.46 | 10.00 | 19.00 | 13.98 | 13.35 | 13.57 | 4,630,191 | 05:00:05 |
From May 2019 to May 2024
By Michael Dabaie
Fitch Ratings said it placed Pfizer Inc. (PFE) ratings on Rating Watch Negative.
Pfizer's proposed deal for Array BioPharma Inc. (ARRY) makes strategic sense, according to Fitch, increasing its presence in oncology. Pfizer this week agreed to buy Array for $10.64 billion in cash.
Fitch said it expects the acquisition will increase leverage, which is already currently stressed for Pfizer's current "A+" rating.
"The company continues to demonstrate little appetite for reducing leverage, despite the more tax-efficient access to its international cash generation provided by 2017 tax reform," Fitch said.
The ratings agency said it will resolve the Negaive Watch when the deal closes and it anticipates a one-notch downgrade of the Long-Term Issuer Default Rating to "A" is likely.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 19, 2019 14:23 ET (18:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Array Technologies Chart |
1 Month Array Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
